This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Novak, G. P. Articles by Siddique, Q. Search for Related Content PubMed PubMed Citation Articles by Novak, G. P. Articles by Siddique, Q. Social Bookmarking                   What's this?

Risk of Excessive Weight Gain in Epileptic Children Treated with Valproate

Division of Neurology, Schneider Children's Hospital, Long Island Jewish Medical Center, New Hyde Park, NY, gpn325{at}aol.com

Joseph Maytal, MD

Division of Neurology, Schneider Children's Hospital, Long Island Jewish Medical Center, New Hyde Park, NY

Anna Alshansky, MD

Division of Neurology, Schneider Children's Hospital, Long Island Jewish Medical Center, New Hyde Park, NY

Lydia Eviatar, MD

Division of Neurology, Schneider Children's Hospital, Long Island Jewish Medical Center, New Hyde Park, NY

Rosemarrie Sy-Kho, MD

Division of Neurology, Schneider Children's Hospital, Long Island Jewish Medical Center, New Hyde Park, NY

Qazi Siddique

Division of Neurology, Schneider Children's Hospital, Long Island Jewish Medical Center, New Hyde Park, NY

We sought to identify factors associated with excessive weight gain in children treated with valproate, excluding patients fed by gastrostomy or treated with medications known to affect appetite (eg, stimulants). Weight and height were recorded before treatment and at the time of follow-up; a measure of adiposity, body mass index, was computed and expressed in kg/m2, and weight and height for age were converted to Z-score. Putative risk factors included sex, age at start of treatment, monotherapy at start of treatment, duration of follow-up, mental retardation, seizure type (generalized or partial), etiology (idiopathic or cryptogenic versus remote symptomatic), and dose of valproate. Fifty-five children (30 girls, 25 boys), ranging in age at the start of therapy from 1.8 to 16.9 years were followed for 8.6 to 33.8 months. Forty-three patients had primarily generalized seizures, 34 had idiopathic or cryptogenic epilepsy (including 30 with generalized idiopathic epilepsy), and 18 had mental retardation. Valproate was the first antiepileptic drug for 21 patients, and 43 were on monotherapy at the time of follow-up. Height Z-score decreased significantly in girls but was stable in boys. There was a significant increase in body mass index and in weight Z-score. Body mass index was greater than the 90th percentile for age in 14 patients at the start of treatment and in 20 patients at follow-up. Decrease in height Z-score was significantly correlated with female sex and duration of follow-up. Changes in weight Z-score and body mass index were significantly correlated with initial weight Z-score and initial body mass index, respectively, but not with age at start of therapy, duration of follow-up, sex, seizure type, etiology, dose of valproate, or monotherapy. (J Child Neurol 1999; 14:490-495).

Journal of Child Neurology, Vol. 14, No. 8, 490-495 (1999)
DOI: 10.1177/088307389901400802


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Sharpe, T. Wolfson, and D. A. Trauner Weight Gain in Children Treated With Valproate J Child Neurol, March 1, 2009; 24(3): 338 - 341. [Abstract] [PDF]

				S. Grosso, R. Mostardini, B. Piccini, and P. Balestri Body Mass Index and Serum Lipid Changes During Treatment with Valproic Acid in Children with Epilepsy Ann. Pharmacother., January 1, 2009; 43(1): 45 - 50. [Abstract] [Full Text] [PDF]

				K. Aydin, A. Serdaroglu, C. Okuyaz, A. Bideci, and K. Gucuyener Serum Insulin, Leptin, and Neuropeptide Y Levels in Epileptic Children Treated With Valproate J Child Neurol, October 1, 2005; 20(10): 848 - 851. [Abstract] [PDF]

				D. C. Lagace, R. S. McLeod, and M. W. Nachtigal Valproic Acid Inhibits Leptin Secretion and Reduces Leptin Messenger Ribonucleic Acid Levels in Adipocytes Endocrinology, December 1, 2004; 145(12): 5493 - 5503. [Abstract] [Full Text] [PDF]

				R. D. Sheth Metabolic concerns associated with antiepileptic medications Neurology, November 23, 2004; 63(10_suppl_4): S24 - S29. [Abstract] [Full Text]

				V. Biton, P. Levisohn, S. Hoyler, A. Vuong, and A. E. Hammer Lamotrigine Versus Valproate Monotherapy--Associated Weight Change in Adolescents With Epilepsy: Results From a Post Hoc Analysis of a Randomized, Double-Blind Clinical Trial J Child Neurol, February 1, 2003; 18(2): 133 - 139. [Abstract] [PDF]

				R. D. Sheth Adolescent Issues in Epilepsy J Child Neurol, February 1, 2002; 17(2_suppl): 2S23 - 2S27. [Abstract] [PDF]

				V. Biton, W. Mirza, G. Montouris, A. Vuong, A.E. Hammer, and P.S. Barrett Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy Neurology, January 23, 2001; 56(2): 172 - 177. [Abstract] [Full Text] [PDF]